These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33116371)

  • 1. Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center.
    Jang K; Ahn J; Sohn J; Hwang DD
    Clin Ophthalmol; 2020; 14():3211-3218. PubMed ID: 33116371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
    Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT
    Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
    Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Complications of intravitreal injections--own experience].
    Jamrozy-Witkowska A; Kowalska K; Jankowska-Lech I; Terelak-Borys B; Nowosielska A; Grabska-Liberek I
    Klin Oczna; 2011; 113(4-6):127-31. PubMed ID: 21913440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
    Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
    Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral same-session intravitreal injections of anti-vascular endothelial growth factors.
    Abu-Yaghi NE; Shokry AN; Abu-Sbeit RH
    Int J Ophthalmol; 2014; 7(6):1017-21. PubMed ID: 25540758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
    Yoshimoto M; Takeda N; Yoshimoto T; Matsumoto S
    J Med Case Rep; 2021 Jul; 15(1):403. PubMed ID: 34311786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy.
    Lima LH; Zweifel SA; Engelbert M; Sorenson JA; Slakter JS; Cooney MJ; Klancnik JM; Yannuzzi LA; Freund KB
    Retina; 2009 Oct; 29(9):1213-7. PubMed ID: 19934815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
    Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
    Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
    Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
    Omay E; Elgin U; Sen E; Yilmazbas P
    Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thirteen years of intravitreal anti-vascular endothelial growth factor therapy: the promises and burdens of a paradigm shift told from the perspective of the largest retina service in Norway.
    Jørstad ØK; Steffensen LA; Eriksen K; Bragadóttir R; Moe MC
    Acta Ophthalmol; 2020 Dec; 98(8):774-779. PubMed ID: 31264363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents.
    Ruão M; Andreu-Fenoll M; Dolz-Marco R; Gallego-Pinazo R
    Clin Ophthalmol; 2017; 11():299-302. PubMed ID: 28203056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure.
    Arslan GD; Guven D; Alkan AA; Kacar H; Demir M
    Cutan Ocul Toxicol; 2019 Dec; 38(4):344-348. PubMed ID: 31092017
    [No Abstract]   [Full Text] [Related]  

  • 19. Bilateral simultaneous intravitreal injections in the office setting.
    Bakri SJ; Risco M; Edwards AO; Pulido JS
    Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
    Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.